NOVARTIS FDA Approval NDA 021877

NDA 021877

NOVARTIS

FDA Drug Application

Application #021877

Documents

Letter2005-11-01
Letter2009-12-24
Label2009-12-16
Label2012-02-06
Letter2009-12-24
Letter2012-02-07
Label2005-11-01
Label2009-12-16
Review2006-01-06
Letter2018-07-06
Label2018-11-30
Letter2018-12-20
Letter2019-08-01
Label2019-08-02
Label2022-12-15
Letter2022-12-16

Application Sponsors

NDA 021877NOVARTIS

Marketing Status

Prescription001

Application Products

001INJECTABLE;INTRAVENOUS250MG/50ML (5MG/ML)1ARRANONNELARABINE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2005-10-28PRIORITY
LABELING; LabelingSUPPL2AP2009-12-15STANDARD
LABELING; LabelingSUPPL5AP2012-02-06STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL6AP2015-06-04PRIORITY
LABELING; LabelingSUPPL8AP2018-07-03STANDARD
LABELING; LabelingSUPPL9AP2018-11-29STANDARD
EFFICACY; EfficacySUPPL10AP2019-07-31STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL12AP2019-08-02STANDARD

Submissions Property Types

ORIG1Null10
SUPPL2Null6
SUPPL5Null7
SUPPL6Null14
SUPPL8Null15
SUPPL9Null6
SUPPL10Null7

TE Codes

001PrescriptionAP

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21877
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.